Navigation Links
Taipan venom no snake oil

Australian snakes' venom could provide the next generation of human therapeutic drugs.

A blood-clotting protein in taipan venom has been identified by Queensland University of Technology PhD researcher Liam St Pierre to rapidly stop excessive bleeding during vascular surgery and major trauma.

The genetic code for the toxin, Factor X (Factor Ten), was identified by PhD researcher Liam St Pierre from QUT's School of Life Sciences who studied the venom of eight of Australia's deadliest land snakes for their therapeutic potential.

His study focussed on the genes in the coastal taipan's venom that are responsible for the pro coagulant or blood clotting agent called Factor X which could stem blood flow in a matter of seconds.

A drug lead based on Factor X is being evaluated for clinical trials by bio pharmaceutical development company QRxPharma.

"Australian snakes literally have a two-pronged attack when they bite their prey," Dr St Pierre said.

"Firstly, venom injection causes massive blood clots instantaneously followed by paralysis as a result of neurotoxins which eventually immobilise and kill the victim."

Dr St Pierre said mammals and snakes naturally produced a small amount of Factor X in their livers.

"Snakes produce a more stable and faster acting form of Factor X in their venom which is the only source of Factor X other than mammalian livers," he said.

"They have developed the ability to deliver massive fatal doses of Factor X to specifically target the systems ofmammals."

Dr St Pierre studied the venom of the inland and coastal taipan, the common brown, the red bellied black, the mulga, the rough-scaled snake, Stephens banded snake and the tiger snake.

"Only the mulga did not have Factor X as it has developed its own unique mechanism of killing."

Dr St Pierre said snake venom was a huge untapped source of potential drug therapies.

His study is the most detailed ever conducted on the genes responsible for Australian snakes' toxins. It is hoped a comprehensive study of all the venom components from Australian snakes may yield further novel components thatcould be targeted as human drugs.


'"/>

Source:Research Australia


Related biology news :

1. Researchers find first evidence of venom system in extinct mammal
2. Evolution mystery: Spider venom and bacteria share same toxin
3. Stanford snake venom study shows that certain cells may eliminate poison
4. Radioactive scorpion venom for fighting cancer
5. Tarantula venom and chili peppers target same pain sensor
6. Nonvenomous Asian snakes borrow defensive poison from toxic toads
7. Venom doc tracks down snake bioweapons
8. Researchers reveal secrets of flying snakes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 27, 2017 , ... Arrowhead Publishers is pleased to announce ... to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, ... in the treatment of various types of pain. There are also extended networking ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... the 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator ... forms of media to advocate for science, as he explains how innovation and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
Breaking Biology Technology: